153 related articles for article (PubMed ID: 16824756)
1. Identification and structure-based optimization of novel dihydropyrones as potent HCV RNA polymerase inhibitors.
Li H; Tatlock J; Linton A; Gonzalez J; Borchardt A; Dragovich P; Jewell T; Prins T; Zhou R; Blazel J; Parge H; Love R; Hickey M; Doan C; Shi S; Duggal R; Lewis C; Fuhrman S
Bioorg Med Chem Lett; 2006 Sep; 16(18):4834-8. PubMed ID: 16824756
[TBL] [Abstract][Full Text] [Related]
2. NMR reveals the intrinsically disordered domain 2 of NS5A protein as an allosteric regulator of the hepatitis C virus RNA polymerase NS5B.
Bessa LM; Launay H; Dujardin M; Cantrelle FX; Lippens G; Landrieu I; Schneider R; Hanoulle X
J Biol Chem; 2017 Nov; 292(44):18024-18043. PubMed ID: 28912275
[TBL] [Abstract][Full Text] [Related]
3. In vitro resistance study of AG-021541, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
Shi ST; Herlihy KJ; Graham JP; Fuhrman SA; Doan C; Parge H; Hickey M; Gao J; Yu X; Chau F; Gonzalez J; Li H; Lewis C; Patick AK; Duggal R
Antimicrob Agents Chemother; 2008 Feb; 52(2):675-83. PubMed ID: 18070954
[TBL] [Abstract][Full Text] [Related]
4. The discovery of finger loop inhibitors of the hepatitis C virus NS5B polymerase: status and prospects for novel HCV therapeutics.
Beaulieu PL
IDrugs; 2006 Jan; 9(1):39-43. PubMed ID: 16374732
[TBL] [Abstract][Full Text] [Related]
5. Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors.
Gopalsamy A; Lim K; Ciszewski G; Park K; Ellingboe JW; Bloom J; Insaf S; Upeslacis J; Mansour TS; Krishnamurthy G; Damarla M; Pyatski Y; Ho D; Howe AY; Orlowski M; Feld B; O'Connell J
J Med Chem; 2004 Dec; 47(26):6603-8. PubMed ID: 15588095
[TBL] [Abstract][Full Text] [Related]
6. Allosteric inhibitors of hepatitis C polymerase: discovery of potent and orally bioavailable carbon-linked dihydropyrones.
Li H; Linton A; Tatlock J; Gonzalez J; Borchardt A; Abreo M; Jewell T; Patel L; Drowns M; Ludlum S; Goble M; Yang M; Blazel J; Rahavendran R; Skor H; Shi S; Lewis C; Fuhrman S
J Med Chem; 2007 Aug; 50(17):3969-72. PubMed ID: 17658778
[TBL] [Abstract][Full Text] [Related]
7. SAR and mode of action of novel non-nucleoside inhibitors of hepatitis C NS5b RNA polymerase.
Powers JP; Piper DE; Li Y; Mayorga V; Anzola J; Chen JM; Jaen JC; Lee G; Liu J; Peterson MG; Tonn GR; Ye Q; Walker NP; Wang Z
J Med Chem; 2006 Feb; 49(3):1034-46. PubMed ID: 16451069
[TBL] [Abstract][Full Text] [Related]
8. The monoethyl ester of meconic acid is an active site inhibitor of HCV NS5B RNA-dependent RNA polymerase.
Pace P; Nizi E; Pacini B; Pesci S; Matassa V; De Francesco R; Altamura S; Summa V
Bioorg Med Chem Lett; 2004 Jun; 14(12):3257-61. PubMed ID: 15149686
[TBL] [Abstract][Full Text] [Related]
9. Hydrogen/Deuterium Exchange Kinetics Demonstrate Long Range Allosteric Effects of Thumb Site 2 Inhibitors of Hepatitis C Viral RNA-dependent RNA Polymerase.
Deredge D; Li J; Johnson KA; Wintrode PL
J Biol Chem; 2016 May; 291(19):10078-88. PubMed ID: 27006396
[TBL] [Abstract][Full Text] [Related]
10. Ligand-induced changes in hepatitis C virus NS5B polymerase structure.
Rigat K; Wang Y; Hudyma TW; Ding M; Zheng X; Gentles RG; Beno BR; Gao M; Roberts SB
Antiviral Res; 2010 Nov; 88(2):197-206. PubMed ID: 20813137
[TBL] [Abstract][Full Text] [Related]
11. Multiple virtual screening approaches for finding new hepatitis C virus RNA-dependent RNA polymerase inhibitors: structure-based screens and molecular dynamics for the pursue of new poly pharmacological inhibitors.
Elhefnawi M; ElGamacy M; Fares M
BMC Bioinformatics; 2012; 13 Suppl 17(Suppl 17):S5. PubMed ID: 23282180
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of a benzodiazepine scaffold yields a potent allosteric inhibitor of hepatitis C NS5B RNA polymerase.
Vandyck K; Cummings MD; Nyanguile O; Boutton CW; Vendeville S; McGowan D; Devogelaere B; Amssoms K; Last S; Rombauts K; Tahri A; Lory P; Hu L; Beauchamp DA; Simmen K; Raboisson P
J Med Chem; 2009 Jul; 52(14):4099-102. PubMed ID: 19507864
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors.
Biswal BK; Cherney MM; Wang M; Chan L; Yannopoulos CG; Bilimoria D; Nicolas O; Bedard J; James MN
J Biol Chem; 2005 May; 280(18):18202-10. PubMed ID: 15746101
[TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition.
Biswal BK; Wang M; Cherney MM; Chan L; Yannopoulos CG; Bilimoria D; Bedard J; James MN
J Mol Biol; 2006 Aug; 361(1):33-45. PubMed ID: 16828488
[TBL] [Abstract][Full Text] [Related]
15. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency.
Beaulieu PL; Bös M; Bousquet Y; DeRoy P; Fazal G; Gauthier J; Gillard J; Goulet S; McKercher G; Poupart MA; Valois S; Kukolj G
Bioorg Med Chem Lett; 2004 Feb; 14(4):967-71. PubMed ID: 15013003
[TBL] [Abstract][Full Text] [Related]
16. 1,5-benzodiazepines, a novel class of hepatitis C virus polymerase nonnucleoside inhibitors.
Nyanguile O; Pauwels F; Van den Broeck W; Boutton CW; Quirynen L; Ivens T; van der Helm L; Vandercruyssen G; Mostmans W; Delouvroy F; Dehertogh P; Cummings MD; Bonfanti JF; Simmen KA; Raboisson P
Antimicrob Agents Chemother; 2008 Dec; 52(12):4420-31. PubMed ID: 18852280
[TBL] [Abstract][Full Text] [Related]
17. Discovery of substituted N-phenylbenzenesulphonamides as a novel class of non-nucleoside hepatitis C virus polymerase inhibitors.
May MM; Brohm D; Harrenga A; Marquardt T; Riedl B; Kreuter J; Zimmermann H; Ruebsamen-Schaeff H; Urban A
Antiviral Res; 2012 Aug; 95(2):182-91. PubMed ID: 22580131
[TBL] [Abstract][Full Text] [Related]
18. Non-nucleoside inhibitors of HCV NS5B polymerase. Part 1: Synthetic and computational exploration of the binding modes of benzothiadiazine and 1,4-benzothiazine HCV NS5b polymerase inhibitors.
Hendricks RT; Fell JB; Blake JF; Fischer JP; Robinson JE; Spencer SR; Stengel PJ; Bernacki AL; Leveque VJ; Le Pogam S; Rajyaguru S; Najera I; Josey JA; Harris JR; Swallow S
Bioorg Med Chem Lett; 2009 Jul; 19(13):3637-41. PubMed ID: 19447623
[TBL] [Abstract][Full Text] [Related]
19. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-one (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor.
Li H; Tatlock J; Linton A; Gonzalez J; Jewell T; Patel L; Ludlum S; Drowns M; Rahavendran SV; Skor H; Hunter R; Shi ST; Herlihy KJ; Parge H; Hickey M; Yu X; Chau F; Nonomiya J; Lewis C
J Med Chem; 2009 Mar; 52(5):1255-8. PubMed ID: 19209845
[TBL] [Abstract][Full Text] [Related]
20. N-Acetamideindolecarboxylic acid allosteric 'finger-loop' inhibitors of the hepatitis C virus NS5B polymerase: discovery and initial optimization studies.
Beaulieu PL; Jolicoeur E; Gillard J; Brochu C; Coulombe R; Dansereau N; Duan J; Garneau M; Jakalian A; Kühn P; Lagacé L; LaPlante S; McKercher G; Perrault S; Poirier M; Poupart MA; Stammers T; Thauvette L; Thavonekham B; Kukolj G
Bioorg Med Chem Lett; 2010 Feb; 20(3):857-61. PubMed ID: 20074949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
